{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:54:55Z","timestamp":1771026895340,"version":"3.50.1"},"reference-count":105,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:00:00Z","timestamp":1668902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515011354"],"award-info":[{"award-number":["2019A1515011354"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Angioimmunoblastic T-cell lymphoma (AITL), a type of malignant lymphoma with unique genomic aberrations, significant clinicopathological features, and poor prognosis, is characterized by immune system dysregulation. Recent sequencing studies have identified recurrent mutations and interactions in tet methylcytosine dioxygenase 2 (TET2), ras homology family member A (RHOA), DNA methyltransferase 3 alpha (DNMT3A), and mitochondrial isocitrate dehydrogenase II (IDH2). Notably, since B-cell lymphomas are frequently observed along with AITL, this review first summarizes its controversial mechanisms based on traditional and recent views. Epigenetic regulation represented by TET2 plays an increasingly important role in understanding the multi-step and multi-lineage tumorigenesis of AITL, providing new research directions and treatment strategies for patients with AITL. Here, we review the latest advances in our understanding of AITL and highlight relevant issues that have yet to be addressed in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers14225699","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:13:36Z","timestamp":1669004016000},"page":"5699","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeting TET2 as a Therapeutic Approach for Angioimmunoblastic T Cell Lymphoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Lina","family":"Hu","sequence":"first","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanye","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifeng","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suxia","family":"Lin","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-6600","authenticated-orcid":false,"given":"Shengbing","family":"Zang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2005-03-1083","article-title":"Angioimmunoblastic T-cell lymphoma: A neoplasm of germinal-center T-helper cells?","volume":"106","author":"Grogg","year":"2005","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Rob","year":"2012","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Lucile","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2016.29","article-title":"DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice","volume":"30","author":"Scourzic","year":"2016","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Enami","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1038\/bcj.2016.122","article-title":"Identification of cell-type-specific mutations in nodal T-cell lymphomas","volume":"7","author":"Nguyen","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.4898","article-title":"TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma","volume":"242","author":"Schwartz","year":"2017","journal-title":"J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190601123989","article-title":"Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma","volume":"48","author":"Jae","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood.V126.23.5064.5064","article-title":"Clinical Features and Treatment Outcomes of Angioimmunoblastic T-Cell Lymphoma: An Analysis from a Nationwide Multicenter Registry, Thailand","volume":"126","author":"Chittima","year":"2015","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.humpath.2021.07.012","article-title":"Incidence and clinicopathological features of Follicular T-cell lymphoma in Finland: A population-based immunohistochemical study","volume":"117","author":"Jenni","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/pin.12981","article-title":"RHOA mutation in follicular T-cell lymphoma: Clinicopathological analysis of 16 cases","volume":"70","author":"Hiroaki","year":"2020","journal-title":"Pathol. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAS.0b013e3181971591","article-title":"Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas","volume":"33","author":"Huang","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_17","first-page":"6097","article-title":"Angioimmunoblastic T-cell lymphoma in Taiwan shows a frequent gain of ITK gene","volume":"7","author":"Liang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17763","DOI":"10.18632\/oncotarget.14846","article-title":"Angioimmunoblastic T cell lymphoma: Novel molecular insights by mutation profiling","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/path.5376","article-title":"Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell","volume":"250","author":"Yao","year":"2020","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2019-129560","article-title":"A Comprehensive Analysis of Rhoa Mutation Positive and Negative Angioimmunoblastic T-Cell Lymphomas By Targeted Deep Sequencing, Expression Profiling, and Single Cell Digital Image Analysis","volume":"134","author":"Alexandra","year":"2019","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-021-00200-x","article-title":"Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas","volume":"10","author":"Yingying","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","article-title":"Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Violaine","year":"2021","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41379-019-0254-4","article-title":"The pathological features of angioimmunoblastic T-cell lymphomas with IDH2(R172) mutations","volume":"32","author":"Steinhilber","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1182\/bloodadvances.2021005171","article-title":"Peripheral T-cell lymphoma: Molecular profiling recognizes subclasses and identifies prognostic markers","volume":"5","author":"Marta","year":"2021","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hon.2319","article-title":"Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma","volume":"35","author":"Saillard","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_29","first-page":"E229","article-title":"Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies","volume":"91","author":"Fadela","year":"2004","journal-title":"Bull. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Jehan","year":"2018","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/PAI.0000000000000644","article-title":"A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification","volume":"27","author":"Sebastian","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0092-8674(00)00115-X","article-title":"Ras and Rho GTPases: A family reunion","volume":"103","author":"Hall","year":"2000","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature01148","article-title":"Rho GTPases in cell biology","volume":"420","author":"Sandrine","year":"2002","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sangok","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.coi.2005.04.003","article-title":"Vav-family proteins in T-cell signalling","volume":"17","author":"Tybulewicz","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1182\/blood.V128.22.4104.4104","article-title":"Recurrent VAV1 Abnormalities in Angioimmunoblastic T Cell Lymphoma","volume":"128","author":"Komori","year":"2016","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","article-title":"RhoA G17V is sufficient to induce autoimmunity and promotes T cell lymphomagenesis in mice","volume":"132","author":"Samuel","year":"2018","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The Combination of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, and Romidepsin Is Highly Active in Relapsed\/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.immuni.2015.01.017","article-title":"ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation","volume":"42","author":"Stone","year":"2015","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1172\/JCI92026","article-title":"Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis","volume":"127","author":"Zang","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41389-020-00259-x","article-title":"New preclinical models for angioimmunoblastic T-cell lymphoma: Filling the GAP","volume":"9","author":"Mhaidly","year":"2020","journal-title":"Oncogenesis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-08-594648","article-title":"Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation","volume":"125","author":"Allison","year":"2015","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ng.3610","article-title":"DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12185-015-1738-8","article-title":"Multistep tumorigenesis in peripheral T cell lymphoma","volume":"102","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Maria","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1073\/pnas.1617929114","article-title":"The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development [Medical Sciences]","volume":"113","author":"Rob","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Tayla","year":"2019","journal-title":"Blood"},{"key":"ref_59","first-page":"40","article-title":"Epstein\u2013Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: A review","volume":"52","author":"Mario","year":"2020","journal-title":"Pathology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1096-9896(199805)185:1<79::AID-PATH52>3.0.CO;2-3","article-title":"Frequent detection of Epstein-Barr virus-infected B cells in peripheral T-cell lymphomas","volume":"185","author":"Ho","year":"1998","journal-title":"J. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","article-title":"Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases","volume":"138","author":"Willenbrock","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1084\/jem.194.7.927","article-title":"Survival and clonal expansion of mutating \"forbidden\" (immunoglobulin receptor-deficient) epstein-barr virus-infected b cells in angioimmunoblastic t cell lymphoma","volume":"194","author":"Spieker","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood.V120.21.1607.1607","article-title":"Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe","volume":"120","author":"Marie","year":"2012","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/path.4920","article-title":"Angioimmunoblastic T-cell lymphoma: More than a disease of T follicular helper cells","volume":"242","author":"Lemonnier","year":"2017","journal-title":"J. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/PAS.0b013e3182785610","article-title":"Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin\/Reed-Sternberg cells of B-cell lineage: Both EBV-positive and EBV-negative variants exist","volume":"37","author":"Nicolae","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1440-1827.2012.02858.x","article-title":"Clinicopathological analysis of a composite lymphoma containing both T- and B-cell lymphomas","volume":"62","author":"Suefuji","year":"2012","journal-title":"Pathol. Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/PAS.0b013e31802d68e9","article-title":"Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: Clinical correlation and insights into natural history and disease progression","volume":"31","author":"Charalampia","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Krug, A., Tari, G., Saidane, A., Gaulard, P., Ricci, J.-E., Lemonnier, F., and Verhoeyen, E. (2022). Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality. Cancers, 14.","DOI":"10.3390\/cancers14102392"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"James","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/CCO.0000000000000773","article-title":"Epigenetic focus on angioimmunoblastic T-cell lymphoma: Pathogenesis and treatment","volume":"33","author":"Tari","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: A multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: A non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood.V130.Suppl_1.819.819","article-title":"In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed\/Refractory T-Cell Lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2021-150523","article-title":"The Interim Efficacy of Epigenetic Priming Regimen with Azacytidine and Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma","volume":"138","author":"Ding","year":"2021","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Jessica","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?","volume":"4","author":"Ricky","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors","volume":"102","author":"Peart","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/14737140.8.3.413","article-title":"Histone deacetylase inhibitors in lymphoma and solid malignancies","volume":"8","author":"Walid","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"43295","DOI":"10.18632\/oncotarget.17177","article-title":"Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis","volume":"8","author":"Yun","year":"2017","journal-title":"Oncotarget"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"106948","DOI":"10.18632\/oncotarget.22157","article-title":"Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes","volume":"8","author":"Cedena","year":"2017","journal-title":"Oncotarget"},{"key":"ref_88","first-page":"913","article-title":"Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma","volume":"168","author":"Morgane","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase 1 study","volume":"134","author":"Falchi","year":"2019","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Elizabeth","year":"1999","journal-title":"Nat. Genet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.biochi.2012.05.029","article-title":"Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2\u2019-deoxycytidine in anaplastic large cell lymphoma","volume":"94","author":"Melanie","year":"2012","journal-title":"Biochimie"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/cncr.23463","article-title":"Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"ref_93","first-page":"3908","article-title":"Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells","volume":"9","author":"Benigno","year":"2017","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/acsmedchemlett.8b00474","article-title":"Cytosine-Based TET Enzyme Inhibitors","volume":"10","author":"Chua","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0173","article-title":"A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms","volume":"2","author":"Guan","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1038\/bcj.2017.65","article-title":"Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells","volume":"7","author":"Shenoy","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"709543","DOI":"10.3389\/fonc.2021.709543","article-title":"Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia","volume":"11","author":"Magon","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s42003-020-01220-9","article-title":"Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia","volume":"3","author":"Guan","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e2110758118","DOI":"10.1073\/pnas.2110758118","article-title":"TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia [Genetics]","volume":"118","author":"Bensberg","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"32822","DOI":"10.18632\/oncotarget.25999","article-title":"Vitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor CDKN1A in colon cancer cells","volume":"9","author":"Gerecke","year":"2018","journal-title":"Oncotarget"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.09.013","article-title":"Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies","volume":"467","author":"Zeng","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Li, C., Peng, C., Jiang, Z., Hu, H., Lin, C., Gao, Y., Liu, D., Sun, B., and Wang, D. (2022). Ginkgo biloba Extract Inhibited Cell Proliferation and Invasion by Stimulating TET2 Expression Through miR-29a in Colorectal Carcinoma Cells. DNA Cell Biol., 41.","DOI":"10.1089\/dna.2021.0418"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"21228","DOI":"10.1038\/s41598-020-77962-7","article-title":"Ascorbic acid during the suckling period is required for proper DNA demethylation in the liver","volume":"10","author":"Kawahori","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/ja4028346","article-title":"Ascorbic Acid Enhances Tet-Mediated 5-Methylcytosine Oxidation and Promotes DNA Demethylation in Mammals","volume":"35","author":"Yin","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature12362","article-title":"Vitamin\u2009C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells","volume":"500","author":"Blaschke","year":"2013","journal-title":"Nature"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/22\/5699\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:22:29Z","timestamp":1760145749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/22\/5699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,20]]},"references-count":105,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14225699"],"URL":"https:\/\/doi.org\/10.3390\/cancers14225699","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,20]]}}}